Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2012

View Archived Issues

RP-7047 evaluated for the treatment of acute lymphoblastic lymphoma

New protein kinase inhibitors disclosed by China State Institute of Pharmaceutical Industry

Gynecologic Oncology Group begins phase II trial of dalantercept

FDA committee recommends approval of GSK's H5N1 influenza vaccine candidate

Incyte earns milestone payment from Lilly

Novel procognitive drug developed for the treatment of dementia-like diseases

TAS-117 demonstrates potent antitumor activity alone and in combination

Second-generation Japanese encephalitis vaccine proves effective in healthy children

Results from first-in-human trial of Na-GST-1 hookworm vaccine presented

Scientists at Origenis design novel protein kinase inhibitors

Brazilian researchers disclose new radioactive iodine compounds

Novel JAK3 inhibitors presented by Cellzome (GlaxoSmithKline)

Biota Scientific Management divulges new antibacterial agents

Bristol-Myers Squibb gains option rights for Biocon drug

Novel synaptic vesicle glycoprotein ligands synthesized by UCB

Zaltrap receives positive CHMP opinion for metastatic colorectal cancer

Nerviano Medical Sciences presents new JAK2 inhibitors

Integral Molecular and Crystal Bioscience enter research collaboration

POZEN plans NDA for integrated aspirin therapy following completion of bioavailability study

Dynavax reports findings from FDA advisory committee meeting for Heplisav BLA

Anti-NOD27 antibodies may possibly provide a novel biomarker in SLE

CHMP recommends approval of Novartis's meningococcal group B vaccine

Palobiofarma's PBF-509 to enter first-in-human phase I trial

FDA assigns action date for Orexo's Zubsolv NDA

EMA committee recommends approval of lixisenatide

Janssen Research & Development establishes global trial investigator databank

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...